Hematopoietic Growth Factors, Version 1.2022 Featured Updates to the NCCN Guidelines

The NCCN Guidelines for Hematopoietic Growth Factors provide recommendations for the appropriate use of growth factors in the clinical management of febrile neutropenia (FN), chemotherapy-induced thrombocytopenia (CIT), and chemotherapy-induced ane-mia (CIA). Management and prevention of these sequelae are an integral part of supportive care for many patients undergoing cancer treatment. The purpose of these guidelines is to operationalize the evaluation, prevention, and treatment of FN, CIT, and CIA in adult patients with nonmyeloid malignancies and to enable the patient and clinician to assess management options for FN, CIT, and CIA in the context of an individual patient???s condition. These NCCN Guidelines Insights provide a summary of the important recent updates to the NCCN Guidelines for Hematopoietic Growth Factors, with particular emphasis on the incorporation of a newly developed section on CIT. J Natl Compr Canc Netw 2022;20(5):436???442 doi: 10.6004/jnccn.2022.0026

Automated summary

The NCCN Guidelines provide recommendations for the appropriate use of growth factors in the management of certain conditions in adult patients with nonmyeloid malignancies. The guidelines aim to evaluate, prevent, and treat febrile neutropenia, chemotherapy-induced thrombocytopenia, and chemotherapy-induced anemia, allowing patients and clinicians to assess management options based on individual patient's condition. The recent updates emphasize the incorporation of a newly developed section on chemotherapy-induced thrombocytopenia.